J2g-Mc-Jzjb- A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Loxo-292 To Physicians Choice Of Cabozantinib Or Vandetanib In Patients With Progressive, Advanced, Kinase Inhibitor Naïve, Ret-Mutant Medullary Thyroid Cancer
Posted Date: Mar 4, 2020
- Investigator: Trisha Wise-Draper
- Specialties: Cancer, Head and Neck Cancer, Oncology, Thyroid Cancer
- Type of Study: Drug
The goal of this study is to compare TFFS of patients with progressive, advanced, kinase inhibitor naïve, RET-mutant MTC treated with selpercatinib versus cabozantinib or vandetanib.
Criteria:
To Be Eligible: Must Have Medullary Thyroid Cancer, Measurable Disease, Life Expectancy >3 Months, Ecog 0-2, No Active Cardiovascular Disease Or Severe Infection Or Illness, No Other Malignancy Within 2 Years
Keywords:
Thyroid Cancer, Medullary Thyroid, Head And Neck
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com